hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06343077 id: STUDY-22-00106 briefTitle: Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance overallStatus: RECRUITING date: 2024-01-16 date: 2026-12-31 date: 2026-12-31 date: 2024-04-02 date: 2024-04-02 name: Ashutosh Kumar Tewari class: OTHER name: Oncovir, Inc. briefSummary: This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance. conditions: Prostate Cancer Patients on Active Surveillance studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 114 type: ESTIMATED name: Poly-ICLC intramuscular (IM) injection name: Poly-ICLC, Intertumoral (IT) injection measure: Proportion of subjects without Gleason group upgrade after treatment measure: Proportion of subjects without Gleason group upgrade after treatment measure: Proportion of subjects without Gleason group downgrade after treatment measure: Proportion of subjects without Gleason group downgrade after treatment measure: Number of subjects who experience adverse events per NCI-CTCAE 5.0 measure: Number of subjects who experience adverse events per NCI-CTCAE 5.0 measure: Number of subjects who receive prostate cancer treatment measure: Number of subjects who receive prostate cancer treatment sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Icahn School of Medicine at Mount Sinai (ISMMS) status: RECRUITING city: New York state: New York zip: 10029 country: United States name: Monali Fatterpekar, PhD role: CONTACT email: monali.fatterpekar@mountsinai.org name: Sujit S Nair, PhD role: CONTACT phone: 212-241-7005 email: sujit.nair@mountsinai.org name: Ashutosh K Tewari, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06343064 id: PLB1001/PLB1004-NSCLC-Ib/II-01 briefTitle: Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI overallStatus: RECRUITING date: 2023-06-13 date: 2024-12-31 date: 2025-06-30 date: 2024-04-02 date: 2024-04-02 name: Avistone Biotechnology Co., Ltd. class: INDUSTRY briefSummary: Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC conditions: Non-Small-Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 156 type: ESTIMATED name: Vebreltinib name: PLB1004 measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). measure: Incidence of dose-limiting toxicities (DLT) as defined in the protocol. measure: Overall Response Rate (ORR） measure: Pharmacokinetics of Vebreltinib and PLB1004 : Area under the concentration time curve (AUC) measure: Pharmacokinetics of Vebreltinib and PLB1004: Maximum plasma concentration of the study drug (C-max) measure: Pharmacokinetics of Vebreltinib and PLB1004: Time to maximum plasma concentration of the study drug (T-max) measure: Incidence of Treatment-Emergent Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Pulmonary Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200433 country: China name: Caichun Zhou, PHD role: CONTACT phone: +86-21-65115006 email: caicunzhoudr@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06343051 id: STUDY-23-01681 briefTitle: USCOM in Newly Diagnosed FGR Cases acronym: USCOM FGR overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-06 date: 2024-04-02 date: 2024-04-02 name: Icahn School of Medicine at Mount Sinai class: OTHER briefSummary: The purpose of this research study is to study the use of an ultrasound measurement system (USCOM) for patients with newly diagnosed fetal growth restriction (FGR). This system uses a technology to measure how much blood is being pumped in and out of the heart, which is important for understanding the heart's function in relation to pregnancy. conditions: Fetal Growth Restriction conditions: USCOM studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: USCOM measure: Systemic vascular resistance obtained from USCOM sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mount Sinai Hospital city: New York state: New York zip: 10029 country: United States name: Nicola F Tavella, MPH role: CONTACT phone: 212-241-3888 email: nicola.tavella@mssm.edu name: Rachel J Meislin role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06343038 id: 2023-01868; th23Nicolas briefTitle: Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study acronym: PROGNOSTICS overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2028-06 date: 2028-06 date: 2024-04-02 date: 2024-04-02 name: University Hospital, Basel, Switzerland class: OTHER briefSummary: Researchers will test a new treatment for prostate cancer. This treatment uses an antibody tagged with a small amount of radioactive material. Researchers believe the new antibody might work better than those used before.
Clinical and radiation dosimetry-based dose escalation study, with a classical 3+3 design, to identify the optimal biologic dose (injected activity) of 161Tb-SibuDAB for safe and effective RLT. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 25 type: ESTIMATED name: Injection, 161Tb-SibuDAB,1GBq name: Injection, 177Lu-PSMA-I&T, 1GBq name: Injection, 161Tb-SibuDAB, Dose Escalation measure: Phase Ia: Tumour absorbed dose measure: Phase Ib: Identification of the optimal biological dose of 161Tb-SibuDAB for mCRPC RLT measure: Phase Ia: Estimation of critical organ median absorbed doses measure: Phase Ia: Estimation of the median tumour-to-critical organ absorbed dose ratios measure: Phase Ib: Cumulative median tumour and organ absorbed doses after 4 cycles of 161Tb-SibuDAB RLT measure: Phase Ib: Estimation of the "therapy index" for 161Tb-SibuDAB RLT. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Basel city: Basel zip: 4031 country: Switzerland name: Alin Chirindel, MD role: CONTACT phone: +41 61 328 63 75 email: alin.chirindel@usb.ch name: Guillaume Nicolas, MD role: CONTACT phone: +41 61 265 47 02 email: guillaume.nicolas@usb.ch lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06343025 id: Hasan Kalyoncu University briefTitle: The Effects of Tai Chi and Pilates for Individuals With Prediabetes overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-09 date: 2024-04-02 date: 2024-04-02 name: Nigde Omer Halisdemir University class: OTHER name: Hasan Kalyoncu University briefSummary: The purpose of this study; To investigate the effects of Clinical Pilates and Tai Chi exercises on glycemic control, body composition, balance function and physical activity level in individuals with prediabetes. conditions: PreDiabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Individuals will be divided into 3 groups: Clinical Pilates group, Tai Chi group and Control group. 3 groups. 3 groups will be measured at the same time and then the exercise part will begin. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Outcomes ,Assesor, who will make the evaluations in the first week and after 12 weeks, will not know which group the people are in. whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Pilates Exercises Group name: Tai Chi Exercises Group measure: Glisemic Control measure: Body Composition measure: Balance measure: Physical Activity Level sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06343012 id: 0305900 briefTitle: Caring Leadership Intervention Program for First-Line Nurse Managers overallStatus: COMPLETED date: 2022-07-01 date: 2022-12-31 date: 2022-12-31 date: 2024-04-02 date: 2024-04-02 name: Matrouh University class: OTHER briefSummary: Caring leadership can help first-line nurse managers create a healthy environment, resulting in a positive outcome for nurse staff, patients, and healthcare organizations. conditions: Intervention conditions: Behavior studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A quasi-experimental study design utilized two groups, study and control groups primaryPurpose: OTHER masking: SINGLE maskingDescription: A quasi-experimental study design utilized two groups, study and control groups. whoMasked: PARTICIPANT count: 60 type: ACTUAL name: Caring leadership Intervention program measure: Questionnaire to measure first-line nurse managers' knowledge measure: Questionnaire to measure the managerial actions of first-line nurse managers measure: Questionnaire to assess nurses' perceived first-line nurse managers' caring behavior measure: questionnaire to measure nurse outcomes sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Nursing, Matrouh University city: Marsa Matruh zip: 002 country: Egypt lat: 31.3529 lon: 27.23725 hasResults: False
nctId: NCT06342999 id: 22-012399 briefTitle: Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2035-07 date: 2035-07 date: 2024-04-02 date: 2024-04-10 name: Mauro H. Schenone class: OTHER briefSummary: The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS). conditions: Hypoplastic Left Heart Syndrome studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Fetal Aortic Valvuloplasty Procedure name: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter name: Trek RX and Mini Trek RX Coronary Dilatation Catheter measure: Number of cases in which the procedure was successful measure: Number of cases in which a biventricular repair was achieved measure: Number cases with pulmonary hypertension measure: Number of cases delivered prematurely measure: Number of cases with perinatal death measure: Number of maternal complications sex: FEMALE maximumAge: 45 Years stdAges: CHILD stdAges: ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06342986 id: 2023LS185 id: P01CA111412 type: NIH link: https://reporter.nih.gov/quickSearch/P01CA111412 briefTitle: Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2028-06-30 date: 2029-06-30 date: 2024-04-02 date: 2024-04-26 name: Masonic Cancer Center, University of Minnesota class: OTHER name: National Cancer Institute (NCI) briefSummary: This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer. conditions: Gynecologic Cancer conditions: Ovarian Cancer conditions: Fallopian Tube Cancer conditions: Primary Peritoneal Cavity Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: A minimum of 28 days must separate each Dose Cohort. A minimum of 30 days must separate the 1st and 2nd patient. All patients are assessed for Dose Limiting Toxicity (DLT) primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: FT536 name: Fludarabine name: CY measure: Progression free survival (PFS) measure: Progression free survival (PFS) measure: Overall survival (OS) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342973 id: 5591 briefTitle: Horizontal Ridge Augmentation With Demineralized Bone Allograft Layered With Xenograft - a Case Series overallStatus: RECRUITING date: 2024-03-27 date: 2025-05-30 date: 2025-05-30 date: 2024-04-02 date: 2024-04-02 name: Louisiana State University Health Sciences Center in New Orleans class: OTHER briefSummary: The aim of this case series is to evaluate the outcomes of horizontal ridge augmentation performed using a combination of demineralized freeze-dried bone allograft layered with xenograft bone with a resorbable native collagen membrane. conditions: Alveolar Ridge Deficiency studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single group primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Xenograft and allograft measure: Horizontal bone gain measure: Vital bone percentage measure: Bone shrinkage measure: Surgical complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: LSUHSC School of Dentistry status: RECRUITING city: New Orleans state: Louisiana zip: 70119 country: United States name: Eswar Kandaswamy role: CONTACT phone: 504-941-8272 email: ekanda@lsuhsc.edu name: Eswar Kandaswamy, BDS, MS role: PRINCIPAL_INVESTIGATOR name: Vinayak Joshi, BDS, MS, PhD role: SUB_INVESTIGATOR name: Jeanne St Germain, RDH role: SUB_INVESTIGATOR lat: 29.95465 lon: -90.07507 hasResults: False
nctId: NCT06342960 id: KYV101-003 briefTitle: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3) overallStatus: RECRUITING date: 2022-12-01 date: 2028-10 date: 2029-01 date: 2024-04-02 date: 2024-04-02 name: Kyverna Therapeutics class: INDUSTRY briefSummary: A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis conditions: Lupus Nephritis conditions: Lupus Nephritis - WHO Class III conditions: Lupus Nephritis - WHO Class IV studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: KYV-101 anti-CD19 CAR-T cell therapy name: Standard lymphodepletion regimen measure: Incidence adverse events (AEs) and laboratory abnormalities measure: Frequency of dose limiting toxicities measure: To characterize the pharmacokinetics (PK) measure: To characterize the pharmacodynamics (PD) measure: To characterize the pharmacodynamics (PD) measure: To evaluate disease related biomarkers measure: To evaluate disease related biomarkers measure: To evaluate efficacy measure: To evaluate efficacy measure: To evaluate efficacy measure: To evaluate the immunogenicity (humoral response) of KYV-101 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Carl Gustav Carus Dresden status: RECRUITING city: Dresden country: Germany name: Study Coordinator role: CONTACT lat: 51.05089 lon: 13.73832 facility: University Hospital Erlangen status: RECRUITING city: Erlangen country: Germany name: Study Coordinator role: CONTACT lat: 49.59099 lon: 11.00783 facility: University Hospital Hamburg-Eppendorf status: RECRUITING city: Hamburg country: Germany name: Study Coordinator role: CONTACT lat: 53.57532 lon: 10.01534 hasResults: False
nctId: NCT06342934 id: INT157/20 briefTitle: Radiomics and Machine Learning in the Diagnosis of Ovarian Masses acronym: Multi-AROMA overallStatus: COMPLETED date: 2020-07-22 date: 2023-12-31 date: 2023-12-31 date: 2024-04-02 date: 2024-04-02 name: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano class: OTHER briefSummary: The correct differential diagnosis between benign and malignant adnexal masses is the main goal of preoperative ultrasound diagnostics and is very important to plan the correct treatment for the patient in terms of surgical team (gynecologist oncologist or benign pathology center), surgical access (laparoscopy / laparotomy) and type of surgery (conservative / demolitive).
If the patient decide to participate in the clinical study, the patient will undergo transvaginal ultrasound (eventually supplemented by transabdominal ultrasound in case of large adnexal masses, if the patients are virgo or if the patients will refuse transvaginal approach for any reason). This exam is part of the routine preoperative evaluation for adnexal pathology and therefore the patients don't have to undergo any additional clinical, biochemical or imaging examination, according to national and international guidelines.
Thereafter, the images stored during the preoperative ultrasound will be exported in anonymous format from the ultrasound system, and sent to the coordinating center (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano). There, images will be submet to radiomic analysis through the application of a dedicated software; that will allow to evaluate the intrinsic characteristics of the tissue according to different parameters (shape, intensity, grade of heterogeneity and many others) of the 'pixels' (gray dots) that constitute the ultrasound image.
If the final histological diagnosis is of serous epithelial ovarian cancer, through the use of the same radiomics software described above the investigators will try to identify the intrinsic characteristics of the tissue associated with the presence or absence of the BRCA 1 or 2 mutation conditions: Ovarian Cysts conditions: Ovarian Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ACTUAL name: Ultrasound measure: Diagnosis of malignant ovarian tumor sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano city: Milano state: Lombardia zip: 20133 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06342921 id: ADC189-2022-01 briefTitle: ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection acronym: ADC overallStatus: RECRUITING date: 2022-12-07 date: 2024-06-30 date: 2024-06-30 date: 2024-04-02 date: 2024-04-02 name: Jiaxing AnDiCon Biotech Co.,Ltd class: INDUSTRY briefSummary: The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection.
Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo. conditions: Safety Issues conditions: Effect of Drug studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 675 type: ESTIMATED name: 15 mg ADC189 name: 45 mg ADC189 name: Placebo measure: the severity of influenza measure: the safety of study drug sex: ALL minimumAge: 12 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Rui Jin Hospital status: RECRUITING city: Shanghai state: Shanghai country: China name: Haili Liu, Dr role: CONTACT phone: +862134188900 email: rjhfbgs@rjh.com.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06342908 id: 23-001700 id: NCI-2024-00210 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) briefTitle: A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2027-03-08 date: 2028-01-09 date: 2024-04-02 date: 2024-04-02 name: Jonsson Comprehensive Cancer Center class: OTHER briefSummary: This phase I trial tests the safety and side effects, and best dose of a vaccine (neoantigen-target ppDC) in treating patients with H3 G34-mutant diffuse hemispheric glioma. Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Giving neoantigen-targeted ppDC may be safe, tolerable and/or effective in treating patients with diffuse hemispheric glioma with a H3 G34 mutation. conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Biospecimen Collection name: Dendritic Cell Therapy name: Leukapheresis name: Magnetic Resonance Imaging name: Poly ICLC measure: Incidence of regimen-limiting toxicities measure: Significant increase in gamma-interferon (IFN) gene expression signature measure: Significant clonal T cell expansion measure: Targets of clonal cytotoxic T cell expansion measure: Pro-inflammatory phenotypic changes in immune cell populations measure: Changes in immune cell subset expansion and contraction in T cell and myeloid-derived cell populations measure: Changes of immune cell markers profile in T cell and myeloid-derived cell populations sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: UCLA / Jonsson Comprehensive Cancer Center city: Los Angeles state: California zip: 90095 country: United States name: Sichen C. Li role: CONTACT phone: 310-592-9091 email: sichenli@mednet.ucla.edu name: Anthony C. Wang, MD role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06342895 id: 2020_1113 id: 2022-A00103-40 type: OTHER domain: ID-RCB number, ANSM briefTitle: Interpretation and Optimization of Nutrition in the Intensive Care Units acronym: IONIC overallStatus: RECRUITING date: 2024-04-10 date: 2025-04 date: 2025-09 date: 2024-04-02 date: 2024-04-25 name: Dim3 class: INDUSTRY name: Baxter Healthcare Corporation name: University Hospital, Lille briefSummary: Despite recommendations, inadequate nutritional intake in intensive care unit (ICU) patients remains frequent and can lead to complications such as infections, increased length of stay, prolonged weaning from ventilation, increased long-term mortality, and decreased quality of life after intensive care. Studies have shown that patients only receive up to 50-60% of prescribed calories and proteins due to many factors leading to nutritional support interruptions such as ICU procedures, physical therapy, transport for imaging or invasive procedures outside the ICU, and nutrition intolerance.
Furthermore, this discrepancy between prescribed and delivered nutrition may go largely unnoticed, due to issues concerning inadequate manual or automated monitoring of delivered nutrition. A joint "Call to Action" by ASPEN, the Academy of Nutrition and Dietetics, and the American Society of Health-System Pharmacists stated that parenteral nutrition errors and their contributing factors could be prevented by improving the functionality of in-house Clinical Decision Support Systems and the interfaces between electronic health records (EHRs), automated preparation devices and pharmacy systems.
Nutrow® is a software package designed to support nutritional management based on the calculation of recommended calorie and protein requirements, real-time calculation and monitoring of calorie and protein prescriptions, real-time calculation and monitoring of calories and protein truly delivered to patients, and information feedback to prescribers. Feedim® is a Medical Device Data System (MDDS), designed by Dim3, which transmits information from enteral feeding pumps to third-party software, such as Nutrow®.